U.S. markets open in 8 hours 7 minutes
  • S&P Futures

    4,115.75
    -4.50 (-0.11%)
     
  • Dow Futures

    33,625.00
    -6.00 (-0.02%)
     
  • Nasdaq Futures

    13,788.75
    -20.00 (-0.14%)
     
  • Russell 2000 Futures

    2,225.50
    -5.10 (-0.23%)
     
  • Crude Oil

    59.87
    +0.17 (+0.28%)
     
  • Gold

    1,730.00
    -2.70 (-0.16%)
     
  • Silver

    24.87
    +0.00 (+0.01%)
     
  • EUR/USD

    1.1892
    -0.0026 (-0.21%)
     
  • 10-Yr Bond

    1.6750
    0.0000 (0.00%)
     
  • Vix

    16.91
    +0.22 (+1.32%)
     
  • GBP/USD

    1.3732
    -0.0010 (-0.08%)
     
  • USD/JPY

    109.6780
    +0.3020 (+0.28%)
     
  • BTC-USD

    60,588.39
    +86.54 (+0.14%)
     
  • CMC Crypto 200

    1,295.78
    +1.19 (+0.09%)
     
  • FTSE 100

    6,889.12
    -26.63 (-0.39%)
     
  • Nikkei 225

    29,776.45
    +237.72 (+0.80%)
     

Can-Fite BioPharma's Namodenoson Improves Liver Function, Long Term Data Shows

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Can-Fite BioPharma (NYSE: CANFreports new data from Phase 2 trial evaluating namodenoson in advanced liver cancer, including the overall survival of nearly four years in two patients under treatment.

  • Additional findings show the disappearance of ascites (abnormal buildup of fluid in the abdomen), normal liver function, and good quality of life.

  • In one patient, stable disease was recorded with the disappearance of peritoneal carcinomatosis (late-stage manifestation of several gastrointestinal malignancies).

  • Namodenoson continues to demonstrate a favorable safety profile and is well tolerated with no severe adverse events reported.

  • The company concluded End-of-Phase 2 meetings with the FDA and European Medicines Agency. Both agencies agreed with Can-Fite's proposed pivotal Phase 3 trial design of Namodenoson to treat patients with advanced hepatocellular carcinoma (HCC), with underlying Child-Pugh B7 cirrhosis. 

  • The company can conduct one pivotal trial with 450 subjects for registration in both the U.S. and European markets.

  • Namodenoson has Orphan Drug Designation for HCC in the U.S. and Europe, has Fast Track Status in the U.S., and is currently treating liver cancer patients through a compassionate use program in Israel.

  • Price Action: CANF gained 31.9% at $3.10 in premarket trading on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.